Literature DB >> 3577206

Polymorphism of human cytochrome P-450.

F P Guengerich, D R Umbenhauer, P F Churchill, P H Beaune, R Böcker, R G Knodell, M V Martin, R S Lloyd.   

Abstract

The cytochrome P-450 forms involved in debrisoquine 4-hydroxylation (P-450DB), phenacetin O-deethylation (P-450PA), S-mephenytoin 4-hydroxylation (P-450MP), and nifedipine 1,4-oxidation (P-450NF) have been purified to electrophoretic homogeneity from human liver microsomes. All of these reactions show in vivo polymorphism in humans. Evidence for the roles of the purified proteins in these processes comes from in vitro reconstitution and immunoinhibition studies. The rat orthologs of these enzymes are as follows--P-450DB: P-450UT-H; P-450PA: P-450ISF-G; P-450MP: P-450UT-I; P-450NF: P-450PCN-E. Only in the case of P-450UT-H is the primary rat ortholog the same cytochrome P-450 which catalyses the catalytic reaction under consideration. Reconstitution and immunochemical studies establish that the following reactions are catalysed by the individual P-450s--P-450DB: debrisoquine 4-hydroxylation, sparteine delta 5-oxidation, bufuralol 1'-hydroxylation, encainide O-demethylation, and propanolol 4-hydroxylation; P-450PA: phenacetin O-deethylation; P-450MP: S-mephenytoin 4-hydroxylation and tolbutamide methyl hydroxylation; P-450NF: oxidation of nifedipine and 16 other substituted dihydropyridines, estradiol 2- and 4-hydroxylation, aldrin epoxidation, benzphetamine N-demethylation and 6 beta-hydroxylation of testosterone, androstenedione and cortisol. A cDNA clone has been isolated that corresponds to rat P-450UT-H, as shown by a number of criteria. Studies with this probe establish that the sex and strain variation in debrisoquine 4-hydroxylase and related activities is related to differences in the levels of a 2.0 kb length mRNA present.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3577206     DOI: 10.3109/00498258709043941

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

Review 1.  New concepts affecting the use of antiarrhythmic agents.

Authors:  R L Woosley
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

2.  Ethnic differences in the pharmacokinetics of oral nifedipine.

Authors:  C H Ahsan; A G Renwick; B Macklin; V F Challenor; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

3.  Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots.

Authors:  P R Jackson; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

4.  Metabolism of debrisoquine and susceptibility to breast cancer.

Authors:  J Huober; B Bertram; E Petru; M Kaufmann; D Schmähl
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

5.  The pharmacokinetics of oral nifedipine--a population study.

Authors:  A G Renwick; D R Robertson; B Macklin; V Challenor; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

6.  In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.

Authors:  D J Back; J F Tjia; J Karbwang; J Colbert
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

7.  Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide.

Authors:  D J Back; J Tjia; H Mönig; E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.